Rize Oncology Appoints Daren Graham as Interim CEO Following Roland Boivin's Resignation

Kelowna, British Columbia — July 10, 2025 — NewsWall — Rize Oncology Inc., a clinical-stage pharmaceutical company, has appointed Executive Chairperson Daren Graham as interim CEO, effective July 10, 2025. This follows the resignation of Roland Boivin as CEO and a director.

Mr. Graham's appointment is expected to be temporary while the Board of Directors seeks a permanent replacement.

Mr. Graham acknowledged Roland Boivin's decision to explore new opportunities after leading Rize through a transformative period, including its IPO and the acquisition of STS-201. He will continue to support the company as a consultant for the next six months.

Rize Oncology Inc. focuses on developing STS-201, a small-molecule drug for treating soft tissue sarcoma and other cancers.

Contact: Daren Graham, Executive Chairman, (833) 294-4363 ext. 2, daren@rizeoncology.com

Source: Rize Oncology Inc.